Akili to study EndeavorRx as a COVID-19 brain fog treatment
The digital therapeutic is designed to treat children ages 8 to 12 with ADHD, but the two studies announced this week will focus on an adult population.
Source: mobihealthnews - Category: Information Technology Tags: COVID-19, Population and Public Health, Digital Health, Care, Technology Source Type: news
More News: ADHD | Brain | Children | COVID-19 | Health Management | Information Technology | International Medicine & Public Health | Neurology | Study